Ginsenoside Rb1 Decreases Injury-Induced Vascular Restenosis

人参皂苷 Rb1 减少损伤引起的血管再狭窄

基本信息

  • 批准号:
    7791189
  • 负责人:
  • 金额:
    $ 22.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ginseng root is one of the most widely recognized herbal supplements with increased clinical evidence of potential benefits in cardiovascular diseases. Studies have shown that ginsenosides, active constituents of ginseng, have protective roles in atherosclerotic plaque formation and various vascular injuries. We hypothesize that ginseng root and ginsenoside have protective effects against angioplasty-induced vascular damage and post-angioplasty restenosis. We recently have demonstrated that ginsenoside Rb1 (Rb1) blocks homocysteine (HCY)-induced detrimental effects on endothelial vasomotor function, free-radical production, and eNOS expression. To extend the preliminary studies, we propose a more comprehensive investigation to elucidate the molecular mechanisms, cellular effects, and in vivo influences of Rb1 on HCY- exaggerated cellular stress following vascular injury. Our central hypothesis is that Rb1 effectively blocks HCY-augmented vascular dysfunction and restenosis by maintaining a functional eNOS system and decreasing oxidative stress. Two specific aims are proposed: Specific Aim 1: Determine the molecular mechanisms of Rb1-medicated eNOS rescue and ROS suppression in HCY-induced cellular stress. Hypothesis: both eNOS dysfunction and oxidative stress play important roles in HCY-induced atherogenesis and restenosis. These two systems are intimately related, yet distinct entities. Rb1 exerts its protective effects by modulating eNOS expression and O2.- production. In this aim, we will study the eNOS system by analyzing eNOS expression, activity, and regulation in human coronary artery endothelial cells (HCAECs) (Specific Aim 1a). We will also investigate the sources of reactive oxygen species (ROS) production in HCAECs and determine whether ROS-mediated signaling pathway is involved in HCY-induced endothelial dysfunction (Specific Aims 1b). Specific Aim 2: Determine the effects of Rb1 on HCY-augmented intimal hyperplasia in a post-guide wire injured murine model. A guidewire-induced common carotid artery injury model in Apolipoprotein E deficient (ApoE-/-) mice will be used. Degree and composition of restenosis will be monitored using a molecular imaging techniques and histology methods. This application may potentially lead to a new strategy of incorporating complementary and alternative medicine to ameliorate HCY-associated cellular stress and post-angioplasty intimal hyperplasia. Development of ginseng compounds is a great opportunity given their history of therapeutic applications and recent discoveries of their molecular actions. Our application utilizes a multidisciplinary approach to explore the mechanisms and in vivo effects of Rb1. We hope that this application will establish a solid foundation for large- scale clinical research and potentially provide an alternative treatment strategy for vascular damages and restenosis. PUBLIC HEALTH RELEVANCE: This application utilizes a comprehensive molecular, cellular, and animal model approach to investigate the effects and mechanisms of ginsenoside Rb1 on homocysteine-exaggerated vascular dysfunction. This application may potentially lead to a new strategy of incorporating complementary and alternative medicine to ameliorate risk factor-associated cellular stress. We hope that our investigation will establish a solid foundation for large-scale clinical research and provide an alternative treatment strategy for vascular restenosis in an aging population.
描述(由申请人提供):人参根是最广泛认可的草药补充剂之一,临床证据表明其对心血管疾病具有潜在益处。研究表明,人参皂苷是人参的活性成分,对动脉粥样硬化斑块的形成和各种血管损伤具有保护作用。我们推测人参根和黄芪对血管成形术引起的血管损伤和血管成形术后再狭窄具有保护作用。我们最近已经证明,Rb 1(Rb 1)块同型半胱氨酸(HCY)诱导的内皮血管功能,自由基的产生和eNOS表达的不利影响。为了扩展初步研究,我们提出了一个更全面的调查,以阐明分子机制,细胞的影响,并在体内的影响,Rb 1对HCY夸大细胞应力血管损伤后。我们的中心假设是Rb 1通过维持功能性eNOS系统和降低氧化应激有效地阻断HCY增强的血管功能障碍和再狭窄。提出了两个具体目标:具体目标1:确定在HCY诱导的细胞应激中Rb 1介导的eNOS拯救和ROS抑制的分子机制。假说:内皮型一氧化氮合酶功能障碍和氧化应激在同型半胱氨酸诱导的动脉粥样硬化和再狭窄中起重要作用。这两个系统密切相关,但不同的实体。Rb 1通过调节eNOS表达和O2.-生产在这个目标中,我们将通过分析eNOS在人冠状动脉内皮细胞(HCAECs)中的表达、活性和调节来研究eNOS系统(具体目标1a)。我们还将研究HCAEC中活性氧(ROS)产生的来源,并确定ROS介导的信号通路是否参与HCY诱导的内皮功能障碍(特定目的1b)。具体目的2:确定Rb 1对导丝损伤后小鼠模型中HCY增强的内膜增生的影响。将在载脂蛋白E缺陷(ApoE-/-)小鼠中使用导丝诱导的颈总动脉损伤模型。将使用分子成像技术和组织学方法监测再狭窄的程度和组成。这项应用可能会带来一种新的策略,即结合补充和替代药物来改善HCY相关的细胞应激和血管成形术后内膜增生。人参化合物的开发是一个很好的机会,因为它们的治疗应用历史和最近发现的分子作用。我们的应用程序利用多学科的方法来探索Rb 1的机制和体内效应。我们希望这一应用将为大规模临床研究建立坚实的基础,并有可能为血管损伤和再狭窄提供替代治疗策略。 公共卫生关系:本申请利用全面的分子、细胞和动物模型方法来研究抗Rb 1对同型半胱氨酸夸大的血管功能障碍的影响和机制。这种应用可能会导致一种新的策略,将补充和替代药物,以改善风险因素相关的细胞压力。我们希望我们的研究将为大规模的临床研究奠定坚实的基础,并为老年人群中的血管再狭窄提供替代治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wei Zhou其他文献

Spin Waves Excitations of Co/PtMultilayers
Co/Pt 多层膜的自旋波激发

Wei Zhou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wei Zhou', 18)}}的其他基金

Targeting LKB1-null lung adenocarcinoma with innate immune system
利用先天免疫系统靶向 LKB1 缺失的肺腺癌
  • 批准号:
    10752833
  • 财政年份:
    2023
  • 资助金额:
    $ 22.9万
  • 项目类别:
An integrative approach to disease gene discovery combining genetic variation, gene expression, and epigenetics.
结合遗传变异、基因表达和表观遗传学的疾病基因发现的综合方法。
  • 批准号:
    10581608
  • 财政年份:
    2022
  • 资助金额:
    $ 22.9万
  • 项目类别:
An integrative approach to disease gene discovery combining genetic variation, gene expression, and epigenetics.
结合遗传变异、基因表达和表观遗传学的疾病基因发现的综合方法。
  • 批准号:
    10349878
  • 财政年份:
    2022
  • 资助金额:
    $ 22.9万
  • 项目类别:
Role of orexin/hypocretin circuit in anesthesia and analgesia
食欲素/下丘脑分泌素回路在麻醉和镇痛中的作用
  • 批准号:
    10651642
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Role of orexin/hypocretin circuit in anesthesia and analgesia
食欲素/下丘脑分泌素回路在麻醉和镇痛中的作用
  • 批准号:
    10186780
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Role of orexin/hypocretin circuit in anesthesia and analgesia
食欲素/下丘脑分泌素回路在麻醉和镇痛中的作用
  • 批准号:
    10430182
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Role of orexin/hypocretin circuit in anesthesia and analgesia
食欲素/下丘脑分泌素回路在麻醉和镇痛中的作用
  • 批准号:
    10040369
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
PKC Epsilon in Vascular Dysfunction
PKC Epsilon 在血管功能障碍中的应用
  • 批准号:
    8329950
  • 财政年份:
    2012
  • 资助金额:
    $ 22.9万
  • 项目类别:
PKC Epsilon in Vascular Dysfunction
PKC Epsilon 在血管功能障碍中的应用
  • 批准号:
    8536078
  • 财政年份:
    2012
  • 资助金额:
    $ 22.9万
  • 项目类别:
PKC Epsilon in Vascular Dysfunction
PKC Epsilon 在血管功能障碍中的应用
  • 批准号:
    8698299
  • 财政年份:
    2012
  • 资助金额:
    $ 22.9万
  • 项目类别:

相似海外基金

Development of a balloon angioplasty catheter capable of simultaneous endovascular delivery of liquid therapeutic agents into the vascular wall
开发能够同时将液体治疗剂血管内输送到血管壁的球囊血管成形术导管
  • 批准号:
    10324960
  • 财政年份:
    2021
  • 资助金额:
    $ 22.9万
  • 项目类别:
Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System
使用新型组合通路鞘/球囊系统在血流逆转下简化经股颈动脉血管成形术和支架置入术
  • 批准号:
    10081007
  • 财政年份:
    2020
  • 资助金额:
    $ 22.9万
  • 项目类别:
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    10019316
  • 财政年份:
    2017
  • 资助金额:
    $ 22.9万
  • 项目类别:
Elucidation of appropriate patients for percutaneous transluminal renal angioplasty treatment
阐明适合经皮腔内肾血管成形术治疗的患者
  • 批准号:
    17K09743
  • 财政年份:
    2017
  • 资助金额:
    $ 22.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Novel Angioplasty Catheter for Treatment of Calcified Arteries
开发用于治疗钙化动脉的新型血管成形术导管
  • 批准号:
    MR/P026850/1
  • 财政年份:
    2017
  • 资助金额:
    $ 22.9万
  • 项目类别:
    Research Grant
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    9410026
  • 财政年份:
    2017
  • 资助金额:
    $ 22.9万
  • 项目类别:
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease
治疗性血管生成加血管成形术和支架置入术治疗肾血管疾病的临床前试验
  • 批准号:
    9249339
  • 财政年份:
    2017
  • 资助金额:
    $ 22.9万
  • 项目类别:
Basic research about application of liposomes to prevent stenosis after angioplasty of craniocervical artery stenosis
应用脂质体预防颅颈动脉狭窄血管成形术后狭窄的基础研究
  • 批准号:
    25462205
  • 财政年份:
    2013
  • 资助金额:
    $ 22.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Utility Of Adenosine Stress Cardiac Magnetic Resonance Imaging Following ST Elevation Myocardial Infarction Post Primary Angioplasty
ST 段抬高型心肌梗死初次血管成形术后腺苷应激心脏磁共振成像的效用
  • 批准号:
    nhmrc : 1018161
  • 财政年份:
    2011
  • 资助金额:
    $ 22.9万
  • 项目类别:
    NHMRC Postgraduate Scholarships
Novel Approaches in Treatment of Vascular Injury Following Balloon Angioplasty
治疗球囊血管成形术后血管损伤的新方法
  • 批准号:
    8402612
  • 财政年份:
    2011
  • 资助金额:
    $ 22.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了